Nejm Article | PDF | Wechsler Adult Intelligence Scale | Docosahexaenoic Acid
Adjunctive Dexamethasone for Tuberculous Meningitis in HIV-Positive Adults | NEJM
Monumen-TAL - I dismantle the ASH/ NEJM Talquetamab study | First of the ASH 2022 video series - YouTube
Symmetric Drug-Related Intertriginous and Flexural Exanthema | NEJM
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis | NEJM
Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk | NEJM
Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation | British Journal of Cancer
Risk of Major Gastrointestinal Bleeding With New vs Conventional Oral Anticoagulants: A Systematic Review and Meta-analysis - ScienceDirect
Cancer Clinical Trial Interpretation Videos - YouTube
A Randomized Trial of Intravenous Alteplase before Endovascular Treatment for Stroke | NEJM
Asco 2019 – Polo reveals an overall survival hole | Evaluate
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
PROpel Trial Efficacy – LYNPARZA® (olaparib) for BRCAm mCRPC
Neoadjuvant Chemotherapy for Resectable Colorectal Cancer Liver Metastases: Indications and Results | SpringerLink
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer | NEJM
Noninvasive Imaging Heisenberg Research Group – Heisenberg Radiology Research group of Marc Dewey
Current Oncology | Free Full-Text | Olaparib versus Placebo in Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer: A Cost–Utility Analysis from the Canadian Public Payer’s Perspective
Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer | NEJM
Hypothermic Machine Perfusion in Liver Transplantation — A Randomized Trial | NEJM
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer | NEJM
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer | Journal of Clinical Oncology
Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis | NEJM
